title: Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy.
abstract: Drug-induced lupus erythematosus (dile) syndromes are documented complications of chemotherapeutic agents, including paclitaxel. Subacute cutaneous lupus erythematosus (scle) is a distinct dile syndrome presenting with characteristic annular or papulosquamous skin lesions in a photosensitive distribution with associated high anti-ssa titres. Previously, dile syndromes complicating paclitaxel therapy have been attributed to polyethoxylated castor oil (Kolliphor EL: BASF, Ludwigshafen, Germany), the biologic solvent included in the drug's original formulation (Taxol: Bristol-Myers Squibb, Montreal, QC), rather than the parent chemotherapy molecule. Here, we report a characteristic case of drug-induced scle complicating treatment with nanoparticle albumin bound (nab)-paclitaxel (Abraxane: Celgene, Summit, NJ, U.S.A.), a solvent-free taxane formulation. The pertinent English-language literature is also discussed. This case report is the first to link solvent-free paclitaxel with scle, and it suggests that the parent molecule is responsible for the reaction.
authors.affiliation: Department of Medicine, Dalhousie University, Halifax, NS.
authors.forename: N W D
authors.initials: NW
authors.lastname: Lamond
authors.forename: T
authors.initials: T
authors.lastname: Younis
authors.forename: K
authors.initials: K
authors.lastname: Purdy
authors.forename: M S
authors.initials: MS
authors.lastname: Dorreen
keywords: Nanoparticle albumin-bound paclitaxel; cutaneous drug reactions; nab-paclitaxel; subacute cutaneous lupus erythematosus